Japan Approves Pfizer's Xalacom For Glaucoma
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare Jan. 20 approved Pfizer's Xalacam (latanoprost/ timolol) eye drops for glaucoma and ocular hypertension. Latanoprost and timolol work together to decrease eye pressure in a once-daily formulation that decreases pressure for 24 hours. Xalacom is the first combo glaucoma drug approved in Japan. (Click here for more - Japanese language)
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.